Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Multiple Sclerosis (Jan 2019)

Posted by Matt Breese on Jan 11, 2019

Find me on:

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple sclerosis treatments shows that more than half of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions. 

MMIT-Reality Check-MS_1Q2019Data snapshot as of Q1 2019

Trends: Contracting is prevalent among interferons, where formulary preference drives choice. Via AIS Health.

To read the full Reality Check on Multiple Sclerosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing